AbbVie (ABBV) 10-K 2024 FY Annual report

Exhibit 23

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)Registration Statements (Form S-8 No. 333-185561, Form S-3 No. 333-207422, and Form S-8 No. 333-222107) pertaining to the AbbVie 2013 Incentive Stock Program,

(2)Registration Statement (Form S-8 No. 333-185562) pertaining to the AbbVie 2013 Employee Stock Purchase Plan for Non-U.S. Employees,

(3)Registration Statements (Form S-8 No. 333-185563 and Form S-8 No. 333-222105) pertaining to the AbbVie Deferred Compensation Plan,

(4)Registration Statement (Form S-8 No. 333-185564 and Form S-8 No. 333-282982) pertaining to the AbbVie Savings Program,

(5)Registration Statement (Form S-8 No. 333-204466) pertaining to the Pharmacyclics, Inc. 2014 Equity Incentive Award Plan,

(6)Registration Statement (Form S-8 No. 333-212067) pertaining to the Stemcentrx 2011 Equity Incentive Plan,

(7)Registration Statement (Form S-3 No. 333-238302) pertaining to common stock of AbbVie Inc.,

(8)Registration Statement (Form S-8 No. 333-256045) pertaining to the AbbVie Amended and Restated 2013 Incentive Stock Program,

(9)Registration Statement (Form S-8 No. 333-268192 and Form S-8 No. 333-282981) pertaining to the AbbVie Deferred Compensation Plan and the AbbVie Deferred Compensation Plan Plus,

(10)Registration Statement (Form S-8 No. 333-277293) pertaining to the ImmunoGen, Inc. Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan and the ImmunoGen, Inc. Inducement Equity Incentive Plan, As Amended,

(11)Registration Statement (Form S-8 No. 333-281545) pertaining to the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan, and

(12)Registration Statement (Form S-3 No. 333-262908) pertaining to debt securities of AbbVie Inc.;

of our reports dated February 14, 2025, with respect to the consolidated financial statements of AbbVie Inc. and subsidiaries and the effectiveness of internal control over financial reporting of AbbVie Inc. and subsidiaries included in this Annual Report (Form 10-K) of AbbVie Inc. and subsidiaries for the year ended December 31, 2024.

/s/ Ernst & Young LLP

Chicago, Illinois

February 14, 2025